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Abstract 
Purpose: To investigate the neuroprotective effects of Lycium barbarum polysaccharide (LBP) against 
concomitant cognitive dysfunction and changes in hippocampal CREB-BDNF signaling pathway in 
chronically unpredictable stressed mice. 
Methods: The mice were subjected to different unpredictable stressors for a period of 4 weeks. 
Behavioral tests, including open field (OFT) and Morris water maze (MWMT) tests were used to 
evaluate pharmacological effects. Serum corticosterone levels, protein expression level of BDNF and 
pCREB/CREB in hippocampus were assessed by ELISA, Western blot and immunohistochemistry 
methods, respectively. Morphological changes in pyramidal neurons in the hippocampus were studied 
by Nissl staining.  
Results: LBP improved mice performance in MWMT, indicating that it reversed chronic unpredictable 
stress (CUS)-induced cognitive deficits. LBP treatment reduced serum corticosterone levels and 
prevented neuron loss in the hippocampus. It maintained expression levels of BDNF and 
phosphorylation of CREB in hippocampus during CUS procedure. 
Conclusion: Lycium barbarum polysaccharide protects CREB-BDNF signaling pathway in 
hippocampus and relieves CUS-induced cognitive deficits. These results suggest that Lycium barbarum 
polysaccharides is potentially an alternative neuro-protective agent against stress-induced 
psychopathological dysfunction. 
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Lycium barbarum (wolfberries, Solanaceae) is 
used in traditional Chinese medicine for treating 
diminished visual acuity, dry cough, abdominal 
pain, headache, infertility, and fatigue [1]. Lycium 
barbarum polysaccharides (LBP), the 
polysaccharide extract from Lycium barbarum 
fruit, contains protein, antioxidants, galacturonic 
acid, neutral sugars, arabinose, galactose, 
rhamnose, xylose, glucuronic acid, mannose and 
glucose [1]. In recent years, many 
pharmacological effects of LBP have been 
reported. LBP has hypoglycemic and 
hypolipidemic effects, and it could be used for 
treating type 2 diabetes [2] and cancer [3]. LBP 
improves sexual behavior and increases 
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neurogenesis [4], as well as Alzheimer’s disease 
(AD), colitis, fatigue, glaucoma and stroke [5]. 
 
Pre-clinical and clinical studies on stress have 
demonstrated a wide range of neurochemical 
and morphological alterations that could 
contribute to psychopathological derangements 
such as cognitive disorders [6,7]. Chronic 
unpredictable stress (CUS), which is one of the 
extensive used rodent models in stress related 
mental disorders such as anxiety and depression 
[8]. Exposure to CUS has been shown to induce 
cognitive deficits [7], reduce neurotrophic factors, 
increase corticosterone levels and even 
decrease the number of neurons and glia in 
hippocampus and other cerebral regions [6]. 
 
Brain­derived neurotrophic factor (BDNF), the 
widely spread neurotrophic factor in the brain, 
has extensively been attributed to stress and 
cognitive deficits related synaptic plasticity in 
several brain regions [9]. Calcium/cyclic-AMP 
responsive binding protein (CREB), the upstream 
molecule of BDNF, plays an important role in 
research on memory system and adult 
hippocampal neurogenesis [10]. Studies have 
shown that dysregulation of the CREB–BDNF 
cascade is involved in mental dysfunction in 
stress procedure, and that potentiation of the 
CREB-BDNF signaling pathway could be a 
specific marker of restoration in stress-induced 
cognitive deficits [9].  
 
Behavioral and morphological alterations induced 
by CUS can be reversed by treatment with most 
current anti-depressants such as fluoxetine [11]. 
Fluoxetine treatment can stop the long-term 
stress induced depression and spatial cognitive 
dysfunction [12]. In addition, a single injection of 
fluoxetine can reverse stress-induced damage in 
LTP at synapses from the hippocampus to 
prefrontal cortex in rats [13,14] . However, 
current antidepressants are associated with 
adverse reactions. The use of complementary 
and alternative medicine for management of 
stress-induced psychopathological dysfunction 
has continued to receive serious attention. New 
healing approachs and different measures to 
succeed the impact of chronic stress are 
necessitated, and analysis of selected functional 
foods can provide important leads. 
 
The goal of the current study was to investigate 
whether LBP can produce beneficial effects 
against concomitant cognitive dysfunction in 
chronically stressed mice, and the role of LBP in 
protection of hippocampal neurons from damage. 
The role of LPB in regulation of serum 
corticosterone levels, and up-regulating effect of 
CREB-BDNF signaling pathway in hippocampus 






Lycium barbarum polysaccharide (LBP) was 
purchased from Wolfberry Co. Ltd (Ningxia, 
China, batch no. 64WFBR140301P). Fluoxetine 
was purchased from Eli Lilly & Co (Indianapolis, 
USA). 
 
Animal handling and treatment schedules 
 
All the animal procedures were performed in 
compliance with the Institute of Animal Care and 
Use Committees of Ningxia Medical University. A 
total of 90 adult male ICR mice weighing 20 + 2 
g, were provided by Experimental Animal Center 
of Ningxia Medical University (no. SCXY 2005-
0001). The mice were accommodated 5 per cage 
and acclimatized for 3 days in a room with 
12h:12h light: dark cycle; temperature of 22 ± 2 
oC  and 40 ± 10 %  relative humidity. 
 
After acclimatization, the mice were randomly 
assigned to six groups with 15 mice per 
propylene cage: Normal group (served as 
negative control with no stressor and normal 
feeding in a separate room); Vehicle group 
(served as CUS depression model group): 
stressor plus 0.9 % NaCl); LBP groups (stressor 
plus separate LBP administration at a doses of 
40, 125 and 400 mg/kg)[15] and fluoxetine group 
(acted as positive control): stressor plus 10 
mg/kg fluoxetine). The stress-exposed groups 
were subjected to repeated drug treatment once 
daily between 13:00 and 14:00pm by intragastric 
administration 1h before stress exposure. In this 
experiment, 24 mice died during the CUS 
procedure, leaving about 10 mice in each group. 
The flow chart of the experiment is shown in 
Figure 1 (a). This research was supported by the 
Animal Ethical Committee of Ningxia Medical 
University (approval no. 2016010) according to 
"Principles of Laboratory Animal Care" (NIH 
publication no. 85-23, revised 1985) [16]. 
 
Chronic unpredictable stress procedures 
 
During the experiment, mice in the normal group 
were left undisturbed (except regular cage 
cleaning and feeding) in a separate room. The 
mice in the other groups exposed to CUS were 
housed individually. The CUS procedure was 
carried out according to the method as described 
previously [17,18], but with slight modifications 
as outlined in Supplementary Information.  
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Open-field test and Morris water maze test were 
carried out as previously described [18,19] and 
the details are provided in Supplementary 
Information. 
 
Measurement of serum corticosterone level 
 
Blood samples were collected then centrifuged 
and stored at -80 °C until analysis. Plasma 
corticosterone was measured by ELISA kit 
(Abcam, Cambridge, UK) and Multiskan Go 
(Thermo Fisher scientific, Vantaa, Finland). 
 
Histochemical analysis via Nissl staining 
 
The procedure used is described in 
Supplementary Information. The number of 
stained cells in each field was counted at ×400 
magnification (BX-51, Olympus, Japan), and 
presented as percentage of normal group per 
high-power field. 
 
Immunohistochemical studies of p-CREB and 
BDNF 
 
Sections were stained with BDNF (polyclone, 
1:100, Abcam); phospho-CREB (p-CREB, 
Ser133, monoclonal, 1:800, Cell Signaling). The 
images were acquired at ×400 magnification 
(BX-51, Olympus, Japan). Quantitative 
histological evaluations of related protein 
expression mean density in hippocampus were 
performed by Image-Pro plus 6.0 software 
(Media Cybernetics Inc. MD, USA). 
 
Western blotting analysis 
 
Western blot was carried out using assay kits in 
line with the procedure described in 
Supplementary Information. Image acquisition 
was processed by Super Signal West Pico 
Chemiluminescent Substrate Kit (Thermo 
Scientific, MA, USA) and ChemiDoc XRS + 
imaging system (BIO-RAD, CA, USA). The Mean 
Gray Value of bands was determined by Image J 




All analyses were performed by GraphPad InStat 
3.0 and GraphPad Prism 5.0 software 
(GraphPad Software Inc., USA). Data are 
presented as mean ± SEM. Differences between 
mean values were evaluated by one-way 
analysis of variance (ANOVA). P < 0.05 was 





Chronic LBP treatment enhanced exploration 
of new environment by mice 
 
The OFT results are shown in Figure 1 (b). CUS 
significantly decreased the number of squares 
entered by mice (n = 10, p < 0.01, vs. normal), 
indicating that CUS procedure decreased interest 
of mice in exploring new environment. Post hoc 
analysis revealed that this deficit was relieved by 
LBP treatment at the doses of 40 mg/kg (n = 10, 
p < 0.05, vs. vehicle), 400 mg/kg (n = 10, p < 
0.01, vs. vehicle) and 10mg/kg doses of 
fluoxetine (n = 10, p < 0.01 vs. vehicle).These 
data confirm that CUS modeling was successful 
and indicate that LBP treatment enhanced the 
interest of the mice in exploring new 
environment. 
 
LBP treatment reversed CUS-induced spatial 
learning and memory damage in mice 
 
As shown in Figure 2 (b-d), CUS induced 
significant damage in spatial learning of mice 
(escape latency, n = 8, p < 0.05, vs. normal) and 
memory (percentage of distance in target 
quarter; n = 8, p<0.01, vs. normal; percentage of 
time spent in target quarter; n = 8, p < 0.01, vs. 
normal). Furthermore, the locus diagram shown 
in Figure 2 (a) indicates that the swimming route 
of mice in the vehicle group was completely 
random. Figure 2 (b) shows that LBP reversed 
the spatial learning damage induced by CUS at 
the dose of 400 mg/kg by significantly decreasing 
escape latency. Results of Probe Trials are 
shown in Figure 2 (c) and Figure 2 (d). LBP 
reversed the memory damage induced by CUS 
at a dose of 400 mg/kg by significantly increasing 
the percentage of distance traveled in target 
quarter (n = 8, p < 0.01 vs. vehicle); and the 
percentage of time in target quarter (n = 8, p < 
0.01, vs. vehicle). These results demonstrate 
LBP restored CUS-induced spatial learning and 
memory damage, and suggest that the cognitive 
deficit induced by CUS could be reversed by LBP 
treatment. 
 
Chronic LBP treatment reduced serum 
corticosterone levels in CUS mice 
 
As shown in Figure 1 (c), the level of serum 
corticosterone was significantly higher in 
stressed mice than normal mice (Figure 1 (c). n = 
10, p < 0.01). Post hoc analysis showed that 400 
mg/kg treated LBP had significantly decreased 
the serum corticosterone levels (n = 10, p < 
0.01). These results demonstrate LBP reversed 
the impairment of feedback regulation of the HPA 
axis induced by CUS. 
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Figure 1: Effect of LBP relieve serum corticosterone level.  
Note: In addition of Normal control group, Mice were exposed to CUS for 4 weeks and received a daily gavage 
(i.g) of saline (vehicle), Fluoxetine (Flx; 10 mg/kg) or LBP (40, 125, 400 mg/kg) during this 4 weeks. The success 
of CUS modeling was confirmed by OFT which were conducted 1h after the gavage in the 35th day. (a) The flow 
chart of the experiment. (b) LBP increased the line crossing in the OFT. (c) LBP relieves the CUS-induced serum 
corticosterone increased. The data are expressed as means + SEM (n = 10); *p < 0.05, **p < 0.01, significantly 
different from Vehicle; ##p < 0.01, significantly different from Normal; one-way ANOVA followed by Dunnett test 
 
 
Figure 2: LBSP treatment reversed CUS-induced spatial learning and memory damage in MWMT.  
NOTE: (a) The probe tracks of Probe Trials. (b) LBP decreased the escape latency in learning procedure. (c) 
LBP increase the percentage of time spent in target quarter in Probe Trials. (d) LBP increased the percentage of 
traveled distance in target quarter in Probe Trials. These data are represented as means + SEM (n = 8). *p < 
0.05, **p < 0.01, significantly different from vehicle; #p < 0.05, ##p < 0.01, significantly different from normal; one-
way ANOVA followed by Dunnett test. 
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LBP treatment relieved CUS-induced 
histomorphological changes in the 
hippocampus  
 
Compared with normal pyramidal cells, as shown 
in Figure 3(a) and Figure 3(b), the CUS-induced 
morphological damage in the hippocampal 
neurons was obvious in the CA1 region (n = 6, p 
< 0.05, vs. normal). But，the post hoc analysis 
confirmed that the neuropathological deficits in 
CA1 region were significantly ameliorated by 
LBP (125 and 400 mg/kg) and Fluoxetine (n = 6, 
p < 0.01, vs. vehicle). These results demonstrate 
CUS causes severe loss of pyramidal neurons in 
the hippocampus, and that LBP treatment could 
relieve these neuronal losses. 
 
LBP treatment restored BDNF signaling 
pathway in hippocampus of CUS mice 
 
As shown in Figure 4 (a) and Figure 4 (b), 
unpredictable stress significantly attenuated the 
expression of hippocampal BDNF protein levels 
(n = 6, p < 0.05 vs. normal) in Western blotting 
studies, but this effect was reversed by fluoxetine 
(n = 6, p < 0.01 vs. vehicle) and LBP at a dose of 
400 mg/kg (n = 6, p < 0.01 vs. vehicle). 
Moreover, similar results were seen in 
immunohistochemical studies as shown in Figure 
5 (e) and Figure 5 (f). 
 
The levels of total CREB protein and p-CREB 
were not significantly changed (n = 6, p > 0.05 
vs. normal) in the CUS mice as shown in Figure 
4(c) and Figure 4(d). Similarly, p-CREB/CREB 
ratio was not significantly decreased in the 
hippocampus of vehicle group (n = 6, p > 0.05 
vs. normal) as shown in Figure 4(e), but it was 
significantly increased by fluoxetine (n = 6, p < 
0.05 vs. vehicle) and LBP at the dose of 400 
mg/kg (n = 6, p < 0.05, vs. vehicle). Significant 
increases in p-CREB level were seen (n = 6, p < 
0.05, vs. vehicle) in the hippocampus of CUS 
mice as shown in Figure 4(d).  
 
Analogous results from immunohistochemical 
studies are shown in Figure 5(f). The levels of p-
CREB were significantly decreased by CUS in 
CA1, CA3 and DG (n = 6, p < 0.05, p < 0.01 vs. 
normal), but this effect was reversed by 
fluoxetine (n = 6, p < 0.01 vs. vehicle). LBP 
treatment at doses of 40 and 400 mg/kg 
significantly reversed-CREB expressions in CA1, 
CA3 and DG regions (n = 6, p < 0.01 vs. vehicle). 
On the other hand, LBP at the dose of 125 mg/kg 
significantly increased p-CREB level in CA1 
region (n = 6, p < 0.05 vs. vehicle). Thus, LBP 
enhanced the levels of p-CREB in CUS mice. 
Since LBP also up-regulated BDNF levels, these 
results suggest that LBP can reverse CUS-
induced depression-like behavior and cognitive 
deficits by upgrading CREB-BDNF signaling 
pathway in CUS mice. 
 
 
Figure 3: LBP treatment relieved CUS-induced histomorphology changes in the CA1 region of hippocampus by 
Nissl staining. Note: (a) The representative images of Nissl staining in theCA1region of hippocampus. Note the 
neuronal cell shrinkage of the Vehicle group in CA1 region, as compare to the other groups, and as indicate by 
the black arrows. (b) LBP treatment relieves CUS-induced neuronal loss in CA1 region. The scale bar is 50μm for 
CA1 images. These data are represented as means + SEM (n = 6); **p < 0.01, significantly different from vehicle; 
#p < 0.05, significantly different from normal; one-way ANOVA followed by Dunnett test 
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Figure 4: LBP treatment restores the CUS-induced decrease in the BDNF signaling pathway in the hippocampus 
by Western blotting. Note: (a) The Western blotting results. (b) Western blotting results showed that LBP 
treatment restores the CUS-induced decrease of BDNF in the hippocampus. (c) The changes of hippocampus 
CREB level between CUS and LBP mice were not significant. (d) LBP enhance the p-CREB level of CUS mice. 
(e)  LBP can restore relative ratio of phosphorylation-CREB in hippocampus. These data are represented as 
means + SEM (n =6); *p < 0.05, **p < 0.01, significantly different from Vehicle; #p < 0.05, significantly different 




In the present study, it has been demonstrated 
that LBP can produce protective effects against 
chronic stress-induced cognitive dysfunction in 
mice models by modulating the CREB-BDNF 
signaling pathway in the hippocampus. 
 
The use of complementary and alternative 
medicine by individuals with stress-induced 
psychopathological dysfunction has been on the 
increase [20,21]. Complementary medicine offers 
new hope to patients on account of its greater 
safety and fewer side-effects when compared to 
orthodox medicine. 
 
Wolfbery (Lyciumbarbarum L., Solanaceae), as a 
type of functional food and folk medicine in China 
and East Asia, is now very popular in Western 
countries where it is marketed in form of health 
food products and anti-aging remedy.  As a 
popular folk medicine in China, Wolfbery is used 
in traditional Chinese medicine [1]. LBP is an 
extract from Lyciumbarbarum fruits. It contains 
proteins, antioxidants, galacturonic acid, neutral 
sugars, arabinose, galactose, rhamnose, xylose, 
glucuronic acid, mannose and glucose [1]. 
 
The CUS model is the most adopted animal 
model for use in stress-related mental disorder 
research [6-8].  
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Figure 5: LBP treatment restores the CUS-induced deficit in the BDNF signaling pathway in the 
hippocampus as shown by immunohistochemical staining.  
Note: (a) The synopsis immunohistochemistry picture of hippocampus. (b) – (d): The synopsis 
immunohistochemistry picture of CA1, CA3 and DG region. (e) LBP restores the CUS-induced 
decrease of BDNF in the hippocampus. (f) LBP restores the CUS-induced decrease of p-CREB in the 
hippocampus. The scale bar is 750 μm for hippocampal images (a) and 75μm for CA1, CA3 and DG 
images (b - d) respectively. These data are represented as mean + SEM (n = 6); *p < 0.05, **p < 0.01, 
significantly different from vehicle; #p < 0.05, ##p < 0.01, significantly different from Normal; one-way 
ANOVA followed by Dunnett test 
 
In an attempt to elucidate the effects of chronic 
LBP treatment on stressed animals, a 4-week 
design of stress procedure was employed to 
evaluate the results in this study[8],and the 
effectiveness of CUS procedure was monitored 
by mice performance in the OFT [17-19,22,23]. 
Changes in serum corticosterone levels were 
also measured in order to confirm the anticipated 
effect LBP treatment in CUS mice [24]. The data 
showed that chronic LBP treatment significantly 
improved mice performance in behavioral 
alterations induced by unpredictable stress 
stimulation. Moreover, LBP reversed the 
impaired feedback regulation of the HPA axis 
induced by CUS procedure. 
 
Cognitive impairment is a core endophenotype of 
major depression [6,7].Pretreatment with 
antidepressants can prevent the cognitive deficit 
caused by CUS [7,11]. These results show that 
chronic stress can influence the hippocampus in 
a highly dynamic manner, such as 
spatial learning and memory. Chronic stress can 
produce neuronal loss and nuclear shrinkage in 
pyramidal neurons [11,25]. Studies have shown 
that these neuropathological deficits may be 
related to prolonged activation of the HPA axis 
and corticosteroid during stress, and can be 
reversed by antidepressant treatment [24]. 
 
In the present study, 4 weeks of CUS induced 
cognitive deficits in the performance of adult 
male ICR mice on MWMT was observed, in 
addition to remarkable neuronal morphological 
damage in CA1 region in hippocampus and 
elevation of plasma corticosterone levels. 
Chronic LBP treatment significantly relieved 
impairment of mice spatial learning and memory 
retention during CUS procedure, which is 
accompanied by relief of neuronal loss and 
nuclear shrinkage in pyramidal neurones in the 
CA1 region of the hippocampus.  
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From these results, it is evident that LBP 
ameliorated the behavioral alterations, such as 
cognitive dysfunction, in CUS-treated mice by 
attenuating plasma corticosterone levels and 
producing neuroprotective effects in the 
hippocampus.   
 
BDNF plays an important role in morphological 
integrity of adult neurons and the activity of 
antidepressants in depressed patients, and in 
animal models of stress [9,11-14]. Various stress 
can decrease BDNF levels in the hippocampus, 
but the decrease can be reversed by 
antidepressant treatment. Thus, increases in 
BDNF expression might be a common 
mechanism of action of antidepressants against 
stress.  
 
In this study, it was found that chronic LBP 
treatment can reverse the down-regulated 
expression of BDNF and ameliorate 
neuropathological deficits in hippocampus of the 
CUS mice. In order to further confirm the role of 
BDNF in the protective effect of LBP in CUS-treat 
mice, the effect of LPB on the transcription factor 
CREB activity was studied. CREB is an important 
regulator of BDNF-induced gene expression 
involved in BDNF signaling pathway [9]. The 
level of phosphorylated CREB is reduced in 
animal models of depression and depressed 
patients, and major classes of antidepressants 
can potentiate the level and/or function of 
phosphorylated CREB in several brain regions 
[9,11-14]. Enhancement of the CREB-BDNF 
signaling pathway could be a specific marker of 
restoration of stress-induced cognitive deficits. In 
this study, the results showed that chronic LBP 
treatment potentiated the expression of p-CREB 
in the hippocampus of stressed mice. 
 
This study shows that LBP can produce 
beneficial effects against stress-induced 
cognitive dysfunction in mice models of stress. 
The effect appears to be mediated through the 
up-regulation of the CREB-BDNF signaling 
pathway in the hippocampus. This newly 
discovered effect of LBP provides a new insight 
for understanding the beneficial effects of LBP 





In this study, behavioral pharmacology, 
immunohistochemistry and biochemical assays 
have been employed to demonstrate the neuro-
protective effects of LBP with respect to reversal 
of cognitive dysfunction induced by chronic 
unpredictable stress (CUS) in mice. The results 
suggest that LBP exerts protective effects 
against cognitive dysfunction by reducing serum 
corticosterone levels and preventing neuronal 
morphological damage in the hippocampus, as 
well as up-regulating expression of CREB-BDNF 
signal pathway in the hippocampus during the 
CUS procedure. These results provide a new 
vista for exploiting Lycium barbarum as an 
alternative neuro-protective agent against stress-
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